Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 6Sunitinib 5Bevacizumab 4Sorafenib 3Radiotherapy 3Radiosurgery 3Nivolumab 3Magnetic Resonance Spectroscopy 3Interleukin-2 3Cyclophosphamide 3Axitinib 3tivozanib 2fludarabine phosphate 2durvalumab 2avelumab 2atezolizumab 2Peripheral Blood Stem Cell Transplantation 2Optical Imaging 2Nephrectomy 2Gene Expression Profiling 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2tremelimumab 1temsirolimus 1siltuximab 1sargramostim 1pazopanib 1pamiparib 1milademetan 1lenvatinib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Renal Cell × bintrafusp alfa protein, human × Clear all
NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡